Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine.

@article{Ribeiro1999ElectrocardiographicCD,
  title={Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine.},
  author={Ant{\^o}nio Luiz Pinho Ribeiro and Juliana Beaudette Drummond and Angela C. Volpini and Ana Carolina Magalh{\~a}es Andrade and Val{\'e}ria Maria de Azeredo Passos},
  journal={Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas},
  year={1999},
  volume={32 3},
  pages={297-301}
}
The pentavalent antimonial (Sb5+) meglumine is the drug of choice for the treatment of cutaneous leishmaniasis (CL) in Brazil. Although the cardiotoxicity of high-dose, long-term Sb5+ therapy is well known, the use of low-dose, short-term meglumine has been considered to be safe and relatively free from significant cardiac effects. In order to investigate the cardiotoxicity of low-dose, short-term therapy with meglumine in cutaneous leishmaniasis, 62 CL patients treated with meglumine were… CONTINUE READING